Jely Pharma SRL
1.6 FTEJely Pharma reported total assets of 469,684 € at the end of the 2025 financial year (annual accounts filed with the NBB on 01 Apr 2026), with 1.6 full-time equivalent.
The score of Jely Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +37988 % Total assets -29 % Headcount (avg FTE) +60 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Jely Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 01 Apr 2026
- Year ended 31 Dec 2024filed on 18 Aug 2025
- Year ended 31 Dec 2023filed on 12 Sep 2024
- Year ended 31 Dec 2022filed on 29 Aug 2023
- Year ended 31 Dec 2021filed on 30 Jun 2022
Jely Pharma's financial analysis
- Solvency0.1%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Jely Pharma
Jely Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0635.630.013
- VAT number
- BE0635630013
- Peppol
- Registered · 0208:0635630013 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 19 Aug 2015
- Registered office
- 1315 Incourt
- Size
- Micro · 1.6 FTE
- Latest accounts
- 2025 · filed on 01 Apr 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Jely Pharma (SRL) has been based in Incourt since 2015, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 20,540 € and equity of 381 €; its revenue is not published. With 1.6 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 0.1%, below the median of its sector (41.5%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Jely Pharma
Companies in the same business, of comparable size and area, outside its group.
- MV Pharma Retail sale of pharmaceutical products Saint-Ghislain · balance sheet 469,186 €
- Apotheek Malcorps Retail sale of pharmaceutical products Sint-Truiden · balance sheet 469,570 €
- Mephar Retail sale of pharmaceutical products Sint-Niklaas · balance sheet 470,027 €
- Viesville Pharma Retail sale of pharmaceutical products Pont-à-Celles · balance sheet 470,253 €
- PharmaConseil Retail sale of pharmaceutical products Verviers · balance sheet 468,687 €
- Pharmacie Themlin Retail sale of pharmaceutical products Awans · balance sheet 468,049 €
- Vipharma Retail sale of pharmaceutical products Saint-Ghislain · balance sheet 467,095 €
- Vancophar Retail sale of pharmaceutical products Bierbeek · balance sheet 466,628 €
Frequently asked questions about Jely Pharma
What is the revenue of Jely Pharma?
Jely Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Jely Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0635630013 for Jely Pharma, if the company is VAT-registered. Its company number (CBE) is 0635.630.013.
Where is the registered office of Jely Pharma?
According to the CBE register, the registered office of Jely Pharma is in 1315 Incourt.
What is the equity of Jely Pharma?
At the close of the 2025 financial year, the equity of Jely Pharma amounts to 381 €, a solvency of 0.1% of total assets.
How many people work at Jely Pharma?
1.6 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Jely Pharma?
The register lists 1 active mandates at Jely Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Jely Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →